Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences industry that specializes in radiopharmaceuticals, today announced that it will showcase its new Actinium-225 production facility during this year’s annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 11-14 in Vancouver, British Columbia, Canada.
News | Radiopharmaceuticals and Tracers
SpectronRx to Showcase New Facility for the Global Supply of Actinium-225 at SNMMI 2022

June 13, 2022 — SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences ...

Time June 13, 2022
arrow
Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

June 8, 2022 — NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and ...

Time June 08, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

June 8, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 08, 2022
arrow
Patented artificial intelligence technology eliminates the need for gadolinium-based contrast agents in MRI exams
News | Artificial Intelligence
Imaging Biometrics Submits FDA 510(k) Application for IB Zero G

May 31, 2022 — Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, announced it has submitted an FDA 510(k) ...

Time May 31, 2022
arrow
The global nuclear medicine market size is expected to reach $24.4 billion by 2030, expanding at a CAGR of 13.0% from 2022 to 2030.
Feature | Nuclear Imaging
Global Nuclear Medicine Market Analysis Report

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare Omnipaque iohexol iodinated contrast media (ICM) for radiologic examinations.
News | Contrast Media
New Report Provides Strategies for Managing Contrast Shortage

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
Decision tree for manual review of currently scheduled contrast-enhanced CT examinations in the event that iodinated contrast supply is critically low. CECT = contrast-enhanced CT. GBCA = gadolinium-based contrast agent. NCCT = non-contrast CT. US = ultrasound.
News | Contrast Media
AJR Publishes Best Practices for Iodinated Contrast Media Shortage

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
Dr. Clifford Cassidy, an Assistant Professor in the University of Ottawa's Faculty of Medicine’s Department of Cellular & Molecular Medicine (CMM) and a scientist at The Royal's Institute of Mental Health Research (IMHR), is the paper’s first author. Image courtesy of the Faculty of Medicine, University of Ottawa
News | Magnetic Resonance Imaging (MRI)
Research Suggests Specialized Brain Imaging can Unveil Mysteries of Alzheimer’s Disease, Other Disorders

May 13, 2022 — Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and ...

Time May 13, 2022
arrow
This action has been taken out of an abundance of caution as a result of potential quality issues identified in its manufacturing processes
News | Nuclear Imaging
Novartis Announces Temporary Halt in Production of Lutathera and Pluvicto

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
A schematic of the 99Mo/99mTc production system based on an electron linear accelerator and activated carbon-based 99mTc generator
News | Radiopharmaceuticals and Tracers
New Production Method Promises to End Medical Radioisotope Shortages

April 22, 2022 — A commonly used radioisotope, technetium-99m, used in medical diagnoses regularly suffers from ...

Time April 22, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) released a new online course designed to provide cardiovascular and other nuclear medicine physicians with the knowledge needed to establish a culture of safety and quality in their nuclear imaging laboratories.
News | Nuclear Imaging
New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Time April 13, 2022
arrow
RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion China has sold together with Mevion’s HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China
News | Treatment Planning
Tongji Hospital Selects RayStation

April 7, 2022 — RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion ...

Time April 07, 2022
arrow
Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).
News | Contrast Media
Gadopiclenol Marketing Authorization Dossier Submissions Accepted for Review by EMA and FDA

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

Time April 06, 2022
arrow
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat
News | Prostate Cancer
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

Time March 28, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News | Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

Time March 23, 2022
arrow
CMSU will bring its state-of-the-art AI medical devices to hospitals and local healthcare providers in a unique hands-on experience to create stronger community engagement throughout the year.
News | Digital Radiography (DR)
Canon Medical Systems USA Presents Its First-Ever U.S. Mobile Truck Tour with the Launch of Canon Across America

March 23, 2022 — Canon Medical Systems USA, Inc. (CMSU), a global leader in innovative diagnostic imaging technology, is ...

Time March 23, 2022
arrow
F-18 FDG PET in COVID-19–related CNS disorders: Principal components analysis of spatial covariance pattern (first row) and statistical parametric mapping analysis of metabolic group differences (second to fifth rows) in patients with COVID-19–related encephalopathy, patients with post-COVID-19 syndrome, and patients with post-COVID-19 syndrome and hyposmia compared to healthy controls (n=13). Image Created by PT Meyer, S Hellwig, G Blazhenets and JA Hosp, Medical Center – University of Freiburg, Germany.
News | Coronavirus (COVID-19)
Molecular Imaging Uncovers Effects of COVID-19 on the Brain

March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive ...

Time March 23, 2022
arrow
On March 17, NRG restarted the reactor in Petten, The Netherlands. At around 11 a.m., the capacity of 45 MW has been reached.
News | Nuclear Imaging
NRG High Flux Reactor Back in Full Operation

March 18, 2022 — On March 17, NRG restarted the reactor in Petten, The Netherlands. At around 11 a.m., the capacity of ...

Time March 18, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.
News
SNMMI designates first Radiopharmaceutical Therapy Centers of Excellence

March 16, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the ...

Time March 16, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now